Fairvalue-Calculator Fairvalue-Calculator
EN DE

Verastem, Inc (VSTM) Fair Value & Analysis

Healthcare · US · Market cap $338M

Price$3.85
Fair Value$2.93
Upside-23.9%
Quality95/100
Evidence: Low Range $2.20 – $3.66

Fair value as of: Jun 25, 2026

Analysis

Verastem, Inc (VSTM) currently trades at $3.85, while our model-based Fair Value estimate is $2.93 — implying the stock looks roughly 23.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Verastem, Inc (VSTM) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.93 versus a price of $3.85 — about −24% (overvalued). Model-based estimate, not financial advice.
What is the fair value of VSTM?
Our 21-model fair value for Verastem, Inc is $2.93 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.85.
What is the quality score of VSTM?
Verastem, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.